Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Researchers at the University of Oxford have found that placebo controls are almost never described according to standard reporting guidelines.

Their findings are published today in the European Journal of Clinical Investigation.

Placebo controls are the ‘gold’ standard against which new treatments are often measured. If a new treatment consistently proves to be better than a placebo treatment, then it is taken to be effective. Otherwise, it isn’t.

Co-lead author and Director of the Oxford Empathy Programme, Jeremy Howick, said: ‘There is a fundamental problem with this “gold” standard. Different placebos have very different effects, which then lead to (sometimes, mistaken) inferences about a new treatment’s effects or harms.’

Read more (University of Oxford website)

Jeremey Howick has also written an article for The Conversation 'Placebos: what they’re made of matters'

Similar stories

Parental mental health worsens under new national COVID-19 restrictions

Coronavirus COVID-19 General Research

Parental stress, depression and anxiety have again increased since new national restrictions have been introduced, according to the latest report from the Oxford University-led COVID-19 Supporting Parents, Adolescents, and Children in Epidemics (Co-SPACE) study, based on data from over 6000 UK parents.

£100 million donation from Ineos to create new institute to fight antimicrobial resistance

Awards and Appointments General Innovation

A new state of the art institute for antimicrobial research is to open at Oxford University thanks to a £100 million donation from Ineos.

RECOVERY trial closes recruitment to convalescent plasma treatment for patients hospitalised with COVID-19

Clinical Trials Coronavirus COVID-19 General Research

The RECOVERY trial was established as a randomised clinical trial to test a range of potential treatments for COVID-19.

Ancient gene mutation found to cause rare hereditary condition

General Research

UK scientists have found that a 7,000-year-old genetic mutation is responsible for a rare form of hereditary motor neuropathy (HMN).